Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Johnson & Johnson, the world’s biggest maker of health-care products, anticipates submitting more than 10 new medicines for approval by regulators worldwide by 2017. There also are plans to improve more than 25 current drugs during the same period, the New Brunswick, New Jersey-based company said today in a statement. The wave of new therapies developed in-house and acquired from outside may keep J&J at the forefront of the industry, where its pharmaceutical business was the fastest growing in 2012 among the largest drugmakers. J&J’s pharmaceutical unit, which accounts for 38 percent of the company’s annual sales, was the main driver of growth in 2011 and 2012, said Michael Weinstein, an analyst at JPMorgan Chase & Co. in New York.
Help employers find you! Check out all the jobs and post your resume.
